tetano
Editor, Senior Moderator
Sci Rep
. 2025 Feb 4;15(1):4179.
doi: 10.1038/s41598-025-88837-0. Multicentre case-control study on the association between COVID-19 vaccines and neurological disorders (COVIVAX)
Elisabetta Pupillo[SUP] 1 [/SUP], Elisa Bianchi[SUP] 1 [/SUP], Ettore Beghi[SUP] 1 [/SUP], Francesco Andrea Pedrazzini[SUP] 2 [/SUP], Angela Giglio[SUP] 2 [/SUP], Edoardo Dalmato Schilke[SUP] 2 [/SUP], Marco Percetti[SUP] 2 [/SUP], Carlo Morotti Colleoni[SUP] 2 [/SUP], Gabriele Mainini[SUP] 2 [/SUP], Paolo Calabresi[SUP] 3 4 [/SUP], Guido Primiano[SUP] 3 4 [/SUP], Giovanni Frisullo[SUP] 3 4 [/SUP], Alessandro Padovani[SUP] 5 [/SUP], Viviana Cristillo[SUP] 5 [/SUP], Andrea Pilotto[SUP] 5 [/SUP], Davide Arici[SUP] 5 [/SUP], Stefano Gipponi[SUP] 5 [/SUP], Gioacchino Tedeschi[SUP] 6 [/SUP], Alessandro d'Ambrosio[SUP] 6 [/SUP], Rosario Domenico Melisi[SUP] 6 [/SUP], Antonio Gallo[SUP] 6 [/SUP], Alvino Bisecco[SUP] 6 [/SUP], Andrea Salmaggi[SUP] 7 [/SUP], Paola Basilico[SUP] 7 [/SUP], Chiara Scaccabarozzi[SUP] 7 [/SUP], Lorenzo Kiferle[SUP] 8 [/SUP], Raffaella Valenti[SUP] 8 [/SUP], Gianluca Avino[SUP] 8 [/SUP], Annamaria Borghi[SUP] 9 [/SUP], Sara Contardi[SUP] 9 [/SUP], Andrea Zini[SUP] 9 [/SUP], Carlo Ferrarese[SUP] 2 10 [/SUP], Simone Beretta[SUP] 11 12 13 [/SUP]
Affiliations
The COVIVAX study assessed the association between COVID-19 vaccination and the risk of common neurological disorders in a multicenter case-control design. Vaccination exposure was compared between individuals with a first diagnosis of a neurological disorder (cases) and age- and sex-matched controls. A total of 624 participants were enrolled, and after random 1:1 matching 265 cases and 265 matched controls (total 530 participants) were included in the analyses. The most frequent neurological diagnosis in cases were stroke (60.4%), multiple sclerosis (11.3%) and seizures (6.4%). The proportion of vaccinated participants was 72.1% among cases and 79.6% among controls. A protective role of vaccination on the risk of developing a new neurological disorder was detected in the unadjusted analysis (OR 0.50; 95% CI 0.29-0.86; p = 0.0114). After adjustment for confounders, the number of vaccination doses received was associated with a reduced risk of developing new neurological disorders for participants aged over 60 years ( p = 0.0472; OR 0.14, 95% CI 0.03-0.68), with pre-existing comorbidities (p = 0.0122; OR 0.04, 95% CI 0.01-0.99) and for stroke (p = 0.0232; OR 0.04, 95% CI 0.02-0.97). The COVIVAX study provided no warning sign regarding an increase in the risk of developing new neurological disorders following COVID-19 vaccination of any type or doses. A potentially protective effect of multiple doses of COVID-19 vaccines against the risk of stroke in people aged over 60 needs to be confirmed by further studies.
Keywords: Attributable risk; COVID-19; Case-control study; Epidemiology; Neurological disorders; Vaccines.
. 2025 Feb 4;15(1):4179.
doi: 10.1038/s41598-025-88837-0. Multicentre case-control study on the association between COVID-19 vaccines and neurological disorders (COVIVAX)
Elisabetta Pupillo[SUP] 1 [/SUP], Elisa Bianchi[SUP] 1 [/SUP], Ettore Beghi[SUP] 1 [/SUP], Francesco Andrea Pedrazzini[SUP] 2 [/SUP], Angela Giglio[SUP] 2 [/SUP], Edoardo Dalmato Schilke[SUP] 2 [/SUP], Marco Percetti[SUP] 2 [/SUP], Carlo Morotti Colleoni[SUP] 2 [/SUP], Gabriele Mainini[SUP] 2 [/SUP], Paolo Calabresi[SUP] 3 4 [/SUP], Guido Primiano[SUP] 3 4 [/SUP], Giovanni Frisullo[SUP] 3 4 [/SUP], Alessandro Padovani[SUP] 5 [/SUP], Viviana Cristillo[SUP] 5 [/SUP], Andrea Pilotto[SUP] 5 [/SUP], Davide Arici[SUP] 5 [/SUP], Stefano Gipponi[SUP] 5 [/SUP], Gioacchino Tedeschi[SUP] 6 [/SUP], Alessandro d'Ambrosio[SUP] 6 [/SUP], Rosario Domenico Melisi[SUP] 6 [/SUP], Antonio Gallo[SUP] 6 [/SUP], Alvino Bisecco[SUP] 6 [/SUP], Andrea Salmaggi[SUP] 7 [/SUP], Paola Basilico[SUP] 7 [/SUP], Chiara Scaccabarozzi[SUP] 7 [/SUP], Lorenzo Kiferle[SUP] 8 [/SUP], Raffaella Valenti[SUP] 8 [/SUP], Gianluca Avino[SUP] 8 [/SUP], Annamaria Borghi[SUP] 9 [/SUP], Sara Contardi[SUP] 9 [/SUP], Andrea Zini[SUP] 9 [/SUP], Carlo Ferrarese[SUP] 2 10 [/SUP], Simone Beretta[SUP] 11 12 13 [/SUP]
Affiliations
- PMID: 39905221
- PMCID: PMC11794632
- DOI: 10.1038/s41598-025-88837-0
The COVIVAX study assessed the association between COVID-19 vaccination and the risk of common neurological disorders in a multicenter case-control design. Vaccination exposure was compared between individuals with a first diagnosis of a neurological disorder (cases) and age- and sex-matched controls. A total of 624 participants were enrolled, and after random 1:1 matching 265 cases and 265 matched controls (total 530 participants) were included in the analyses. The most frequent neurological diagnosis in cases were stroke (60.4%), multiple sclerosis (11.3%) and seizures (6.4%). The proportion of vaccinated participants was 72.1% among cases and 79.6% among controls. A protective role of vaccination on the risk of developing a new neurological disorder was detected in the unadjusted analysis (OR 0.50; 95% CI 0.29-0.86; p = 0.0114). After adjustment for confounders, the number of vaccination doses received was associated with a reduced risk of developing new neurological disorders for participants aged over 60 years ( p = 0.0472; OR 0.14, 95% CI 0.03-0.68), with pre-existing comorbidities (p = 0.0122; OR 0.04, 95% CI 0.01-0.99) and for stroke (p = 0.0232; OR 0.04, 95% CI 0.02-0.97). The COVIVAX study provided no warning sign regarding an increase in the risk of developing new neurological disorders following COVID-19 vaccination of any type or doses. A potentially protective effect of multiple doses of COVID-19 vaccines against the risk of stroke in people aged over 60 needs to be confirmed by further studies.
Keywords: Attributable risk; COVID-19; Case-control study; Epidemiology; Neurological disorders; Vaccines.